Study on Indications of "Bard" PowerPort Isp Implantable Port
NCT ID: NCT02887261
Last Updated: 2019-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2016-05-31
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fully Coated, Removable, Self-expanding Oesophageal Stents for Preventing Strictures Following Complete Barretts Excision.
NCT01554280
Trial Using 125I Embedded Stent in Patients With Advanced Esophageal Cancer
NCT00826813
a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent
NCT01054274
Study of Gastroduodenal Metallic Stent vs Gastrojejunostomy
NCT02784470
Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
NCT02971345
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients with cancer need to regularly receive imaging surveillance to evaluate treatment efficacy. Besides, the surveillance imaging provides benchmark reference for adjustment of treatment plan. To provide the enhanced quality of image, contrast media is expected to be administered at certain injection rates. Such requested injection rates would generate high pressures due to the sticky nature of the contrast media. Most of the time, the pressures incurred are far beyond the pressure setting of the conventional ports which mostly in the range of 10 \~ 12 atmospheric pressures (approximately 145 \~ 175 psi) and may cause device rupture or burst. Venipuncture is still unavoidable for oncologic patients with intravenous port implanted for administering contrast media so that patients' vessels cannot be completely protected from repeated venipunctures. Besides, patients' native vessel has its own infusion pressure limitation. Extravasation of contrast media to peripheral soft tissues would happen to the patients with poor vessels or to those in need for power injection of contrast media. Extravasation of contrast media may lead to cutaneous necrosis at different degrees. Such a consequence not only causes pain to patients, but also postpones the subsequent treatment that cannot be continued until the wound is healed up. The delay of treatment might impact on patients' survival. To avoid such a complication, radiologists are forced to lower the infusion velocity of contrast media and compromise the quality of the image requested by the diagnosis.
Tumor would induce neovascularization process which may trigger abnormal new vessels to form and surround the lesion for providing the requested nutritional support for its growth. Given by this characteristic, the contrast-enhanced image plays an important role in evaluating the degree of tumor invasion. In addition, information regarding relative anatomic relationship between tumor and surrounding vital structure is also crucial for formulation of a treatment plan. However, as medical image is not color but black and white images, images with sharp contrast can present subtle changes of tumor more clearly as reference for evaluation of physicians. If the resectability and the metastatic lesions could be identified from medical images as early as possible, personalized treatment could be planned to achieve better survival rates. Therefore, it is extremely important to acquire a clear medical image. With respect to conventional CT, it can indicate the relative anatomical relationship between tumor and surrounding vital structures, which is a key basis for formulation of treatment plan. Current initial imaging data shows CT images taken after infusion with an implanted port that can endure a high infusion pressure are actually different from those taken after infusion through peripheral vein Theoretically, contrast media administrated via central vein could increase concentration of contrast media within a short time, improving the imaging quality of tissues close to the tumor greatly and reducing the necessity of peripheral venipuncture and the risk of contrast extravasation. Therefore, an implantable port that can endure a high infusion pressure is the only solution to meet the demand both from treatment and from surveillance. Furthermore, venous thrombus is more likely to occur in patients with malignant tumor, which must be prevented as it may cause a higher in-hospital mortality rate. If loosen thrombus delivered by venous return may lead most serious complications, such as pulmonary embolism. Pulmonary artery angiography was used to be the only way for diagnosis. However, with the improvement of imaging technology, computed tomography now could be utilized in diagnosis too. High quality of image may be achieved as long as contrast media is injected at a high velocity but patients might risk getting hurt by extravasation of contrast media. After intravenous port that could endure high injection pressure was available, the characteristic of high volume profile could provide secure vascular route with minimal risk of extravasation. However, there was no agreeable conclusion on how such a device may benefit the survival of the patients. Although the port that can endure a high pressure of infusion can provide a reliable intravenous route and better medical images, the benefits of prognosis which may be brought by such port are still unknown. Besides, the national insurance hasn't reimbursed such new type of infusion port due to limited insurance budget. Therefore, investigators intend to identify the patients suitable for implantation of such port in view of features of imaging and tumor so as to improve prognosis of cancer patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Power Port
patients who received power injectable port
"Bard"PowerPort sip Implantable Port
capable for power injection for contrast media.
Conventional Port
patients who received conventional port ( not power injectable)
Conventional Port
not for power injection for contrast media.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
"Bard"PowerPort sip Implantable Port
capable for power injection for contrast media.
Conventional Port
not for power injection for contrast media.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
C. R. Bard
INDUSTRY
Chang Gung Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ching-Yang Wu, MD
Role: PRINCIPAL_INVESTIGATOR
Chang Gung Memorial Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chang Gung Memorial Hospital
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Charvat J, Linke Z, Horaekova M, Prausova J. Implantation of central venous ports with catheter insertion via the right internal jugular vein in oncology patients: single center experience. Support Care Cancer. 2006 Nov;14(11):1162-5. doi: 10.1007/s00520-006-0073-2. Epub 2006 Apr 5.
Copper CM, Pacanowski JP, Bell JL. The trapezius port: a novel approach for port access. Am Surg. 2005 Feb;71(2):106-9.
Broviac JW, Cole JJ, Scribner BH. A silicone rubber atrial catheter for prolonged parenteral alimentation. Surg Gynecol Obstet. 1973 Apr;136(4):602-6. No abstract available.
Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet. 1979 Jun;148(6):871-5. No abstract available.
Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery. 1982 Oct;92(4):706-12.
Belzunegui T, Louis CJ, Torrededia L, Oteiza J. Extravasation of radiographic contrast material and compartment syndrome in the hand: a case report. Scand J Trauma Resusc Emerg Med. 2011 Feb 4;19:9. doi: 10.1186/1757-7241-19-9.
Azais H, Bresson L, Bassil A, Katdare N, Merlot B, Houpeau JL, El Bedoui S, Meurant JP, Tresch E, Narducci F. Chemotherapy drug extravasation in totally implantable venous access port systems: how effective is early surgical lavage? J Vasc Access. 2015 Jan-Feb;16(1):31-7. doi: 10.5301/jva.5000316. Epub 2014 Oct 16.
Petterson TM, Marks RS, Ashrani AA, Bailey KR, Heit JA. Risk of site-specific cancer in incident venous thromboembolism: a population-based study. Thromb Res. 2015 Mar;135(3):472-8. doi: 10.1016/j.thromres.2014.12.013. Epub 2014 Dec 16.
Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20;33(6):654-6. doi: 10.1200/JCO.2014.59.7351. Epub 2015 Jan 20.
Baptista R, Santiago I, Jorge E, Teixeira R, Mendes P, Curvo-Semedo L, Castro G, Monteiro P, Caseiro-Alves F, Providencia LA. One-shot diagnostic and prognostic assessment in intermediate- to high-risk acute pulmonary embolism: the role of multidetector computed tomography. Rev Port Cardiol. 2013 Jan;32(1):7-13. doi: 10.1016/j.repc.2012.05.020. Epub 2012 Dec 11.
Rice TW. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am. 2000 Aug;10(3):471-85.
Sandha GS, Severin D, Postema E, McEwan A, Stewart K. Is positron emission tomography useful in locoregional staging of esophageal cancer? Results of a multidisciplinary initiative comparing CT, positron emission tomography, and EUS. Gastrointest Endosc. 2008 Mar;67(3):402-9. doi: 10.1016/j.gie.2007.09.006.
Sloof GW. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET. Best Pract Res Clin Gastroenterol. 2006;20(5):941-57. doi: 10.1016/j.bpg.2006.04.004.
Yegin EG, Duman DG. Staging of esophageal and gastric cancer in 2014. Minerva Med. 2014 Oct;105(5):391-411. Epub 2014 Jul 7.
Isenberg G, Chak A, Canto MI, Levitan N, Clayman J, Pollack BJ, Sivak MV Jr. Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc. 1998 Aug;48(2):158-63. doi: 10.1016/s0016-5107(98)70157-9.
Li SH, Rau KM, Lu HI, Wang YM, Tien WY, Liang JL, Lin WC. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2012 Dec;42(6):958-64. doi: 10.1093/ejcts/ezs136. Epub 2012 Mar 30.
Teichgraber UK, Gebauer B, Benter T, Wagner HJ. Central venous access catheters: radiological management of complications. Cardiovasc Intervent Radiol. 2003 Jul-Aug;26(4):321-33. doi: 10.1007/s00270-003-0112-z.
Steuer CE, Behera M, Kim S, Patel N, Chen Z, Pillai R, Saba NF, Shin DM, Owonikoko TK, Khuri FR, Ramalingam SS. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer. 2015 Apr;88(1):80-4. doi: 10.1016/j.lungcan.2015.01.022. Epub 2015 Feb 2.
Wani S, Das A, Rastogi A, Drahos J, Ricker W, Parsons R, Bansal A, Yen R, Hosford L, Jankowski M, Sharma P, Cook MB. Endoscopic ultrasonography in esophageal cancer leads to improved survival rates: results from a population-based study. Cancer. 2015 Jan 15;121(2):194-201. doi: 10.1002/cncr.29043. Epub 2014 Sep 18.
Yen TJ, Chung CS, Wu YW, Yen RF, Cheng MF, Lee JM, Hsu CH, Chang YL, Wang HP. Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma. Dis Esophagus. 2012 Jan;25(1):40-7. doi: 10.1111/j.1442-2050.2011.01204.x. Epub 2011 May 19.
Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005 Jun;129(6):1232-41. doi: 10.1016/j.jtcvs.2004.12.042.
Pfau PR, Perlman SB, Stanko P, Frick TJ, Gopal DV, Said A, Zhang Z, Weigel T. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc. 2007 Mar;65(3):377-84. doi: 10.1016/j.gie.2006.12.015.
Kalha I, Kaw M, Fukami N, Patel M, Singh S, Gagneja H, Cohen D, Morris J. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer. 2004 Sep 1;101(5):940-7. doi: 10.1002/cncr.20429.
van den Hoed RD, Feldberg MA, van Leeuwen MS, van Dalen T, Obertop H, Kooyman CD, van der Schouw YT, de Graaf PW. CT prediction of irresectability in esophageal carcinoma: value of additional patient positions and relation to patient outcome. Abdom Imaging. 1997 Mar-Apr;22(2):132-7. doi: 10.1007/s002619900157.
Tsujimoto H, Ichikura T, Aiko S, Yaguchi Y, Kumano I, Takahata R, Matsumoto Y, Yoshida K, Ono S, Yamamoto J, Hase K. Multidetector-computed tomography attenuation values between the tumor and aortic wall in response to induction therapy for esophageal cancer and its predictive value for aortic invasion. Exp Ther Med. 2012 Feb;3(2):243-248. doi: 10.3892/etm.2011.386. Epub 2011 Nov 22.
Crehange G, Bosset M, Lorchel F, Buffet-Miny J, Dumas JL, Mercier M, Puyraveau M, Maingon P, Bosset JF. Tumor volume as outcome determinant in patients treated with chemoradiation for locally advanced esophageal cancer. Am J Clin Oncol. 2006 Dec;29(6):583-7. doi: 10.1097/01.coc.0000242346.25229.48.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CGMH-IRB-104-3143A3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.